Integer (NYSE:ITGR) Upgraded at Zacks Research

Zacks Research upgraded shares of Integer (NYSE:ITGR) from a strong sell rating to a hold rating in a research note released on Monday,Zacks.com reports.

Several other equities analysts have also recently issued reports on the stock. Truist Financial lifted their price objective on shares of Integer from $97.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a report on Thursday, June 18th. KeyCorp restated an “overweight” rating and issued a $104.00 price target on shares of Integer in a research report on Tuesday. Citigroup upped their price target on Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $97.00 price objective (up from $87.00) on shares of Integer in a research report on Friday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Integer presently has a consensus rating of “Hold” and a consensus price target of $97.00.

Integer Trading Up 0.2%

Shares of Integer stock opened at $96.46 on Monday. The business has a fifty day simple moving average of $92.11 and a 200-day simple moving average of $87.94. Integer has a fifty-two week low of $62.00 and a fifty-two week high of $116.31. The firm has a market cap of $3.28 billion, a price-to-earnings ratio of 24.05, a price-to-earnings-growth ratio of 2.30 and a beta of 0.64. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77.

Integer (NYSE:ITGR) last released its earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). Integer had a return on equity of 12.83% and a net margin of 7.64%.The firm had revenue of $439.58 million for the quarter, compared to analyst estimates of $426.48 million. During the same period in the previous year, the firm earned $1.31 earnings per share. Integer’s revenue was up .5% on a year-over-year basis. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, equities analysts forecast that Integer will post 6.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. EverSource Wealth Advisors LLC raised its position in Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 117 shares in the last quarter. Salomon & Ludwin LLC lifted its stake in shares of Integer by 46.8% in the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 118 shares during the last quarter. Harbor Investment Advisory LLC acquired a new stake in shares of Integer in the 2nd quarter valued at $42,000. TD Private Client Wealth LLC boosted its holdings in Integer by 1,037.5% in the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 415 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its holdings in Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 267 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.